|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
almost 3 years ago
Key Factors Attributing to a Successful Product Launchalmost 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaalmost 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixalmost 3 years ago
Co-creating New Innovationsalmost 3 years ago
The Potential Impact of the IRAalmost 3 years ago
Patient Hubs Continue Growthalmost 3 years ago
Social Media’s Complex Climbalmost 3 years ago
Industry Workforce Seeks Clarityalmost 3 years ago
Cybersecurity Threats & PharmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
